Keywords: strong, data, seroquel, ssri/snri, augmentation, anglo-swedish, drug
Strong data for Seroquel SSRI/SNRI augmentation
Article | 29 May 2006
Anglo-Swedish drug major AstraZeneca has reported strong results from two clinical studies that examined its drug Seroquel (quetiapine fumarate) in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
